Incidence of transfusion‐induced platelet‐reactive antibodies evaluated by specific assays for the detection of human leucocyte antigen and human platelet antigen antibodies

Fontão-Wendel, Rita; Silva, L. C. N.; Saviolo, C. B. R.; Primavera, B.; Wendel, Silvano

doi:10.1111/j.1423-0410.2007.00958.x

Cited by 18 publications

(16 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The PRA-HLA test is considered to be highly sensitive and specific for the identification of HLA class I alloantibodies compared to all other tests 17. Only three patients (19%) were positive to these alloantibodies.…”

Section: Discussionmentioning

confidence: 99%

Identification of platelet refractoriness in oncohematologic patients

Ferreira

Zulli

Soares

et al. 2011

Clinics

View full text Add to dashboard Cite

OBJECTIVES:To identify the occurrence and the causes of platelet refractoriness in oncohematologic patients.INTRODUCTION:Platelet refractoriness (unsatisfactory post-transfusion platelet increment) is a severe problem that impairs the treatment of oncohematologic patients and is not routinely investigated in most Brazilian services.METHODS:Forty-four episodes of platelet concentrate transfusion were evaluated in 16 patients according to the following parameters: corrected count increment, clinical conditions and detection of anti-platelet antibodies by the platelet immunofluorescence test (PIFT) and panel reactive antibodies against human leukocyte antigen class I (PRA-HLA).RESULTS:Of the 16 patients evaluated (median age: 53 years), nine (56%) were women, seven of them with a history of pregnancy. An unsatisfactory increment was observed in 43% of the transfusion events, being more frequent in transfusions of random platelet concentrates (54%). Platelet refractoriness was confirmed in three patients (19%), who presented immunologic and non-immunologic causes. Alloantibodies were identified in eight patients (50%) by the PIFT and in three (19%) by the PRA-HLA. Among alloimmunized patients, nine (64%) had a history of transfusion, and three as a result of pregnancy (43%). Of the former, two were refractory (29%). No significant differences were observed, probably as a result of the small sample size.CONCLUSION:The high rate of unsatisfactory platelet increment, refractoriness and alloimmunization observed support the need to set up protocols for the investigation of this complication in all chronically transfused patients, a fundamental requirement for the guarantee of adequate management.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of platelet refractoriness in oncohematologic patients

Ferreira

Zulli

Soares

et al. 2011

Clinics

View full text Add to dashboard Cite

show abstract

“…18 These PLT donors were also selected for HPA antigens including PLTs homozygous for HPA-1b, -2b, and -5b.…”

Section: Pift and Maipa Assay For Detection Of Alloantibodiesmentioning

confidence: 99%

Immune‐mediated pancytopenia induced by oxaliplatin: a case report

et al. 2010

View full text Add to dashboard Cite

show abstract

“…[35] A patient with alloimmunization becomes a challenge for the clinicians and transfusion medicine specialists because of the accelerated destruction of transfused platelets by the respective alloantibodies. [6]…”

Section: Introductionmentioning

confidence: 99%

Prevalence of platelet reactive antibodies in patient′s refractory to platelet transfusions

Agarwal¹,

Chatterjee²,

Sen³

et al. 2014

Asian J Transfus Sci

View full text Add to dashboard Cite

Introduction & Aims:Though platelet transfusions have greatly reduced the incidence of major haemorrhagic complications associated with the management of haematological and oncological disorders, refractoriness to infused platelets becomes a major clinical problem for many of these patients.Materials and methods:The present study was done to determine the percentage of platelet alloimmunisation due to platelet-reactive antibodies in 340 patients with hematologic or oncologic diseases who had received multiple transfusions (> 10) of blood and blood components and showed platelet refractoriness in 1-hour post transfusion sample.Results:Platelet-reactive antibodies were detected in the sera of 127 out of 340 patients (37.35%) who received multiple transfusions (> 10) and showed platelet refractoriness.Conclusion:Platelet-reactive antibodies appear to be an important cause of platelet refractoriness in patients of acute leukaemia, aplastic anaemia, NHL, MDS and multiple myeloma receiving multiple platelet transfusions. Platelet refractoriness in patients of ITP and chronic leukaemia appears to be due to other causes and not due to platelet-reactive antibodies.

show abstract

Incidence of transfusion‐induced platelet‐reactive antibodies evaluated by specific assays for the detection of human leucocyte antigen and human platelet antigen antibodies

Cited by 18 publications

References 24 publications

Identification of platelet refractoriness in oncohematologic patients

Identification of platelet refractoriness in oncohematologic patients

Immune‐mediated pancytopenia induced by oxaliplatin: a case report

Prevalence of platelet reactive antibodies in patient′s refractory to platelet transfusions

Contact Info

Product

Resources

About